Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVeris has entered into an option agreement with the University of Massachusetts at Amherst for exclusive patent rights to a unique vaccine candidate for chlamydia, the most frequently reported infectious disease in the US.
Subscribe to our email newsletter
Under the agreement with the University of Massachusetts at Amherst (UMA), BioVeris acquired a first option for exclusive rights to commercialize products for possible use in the prevention, diagnosis and treatment of all chlamydial infections, including the disease, chlamydia, caused by the bacterium, chlamydia trachomatis.
BioVeris and UMA also entered into a separate sponsored research agreement under which BioVeris will sponsor up to $600,000 of research at UMA through 2006 aimed at developing a vaccine candidate. If the company exercises its option for exclusive rights to commercialize products, it will pay a license issue fee, as well as milestones fees for initiating and completing human clinical trials and securing regulatory approvals, and royalties on product sales.
There is no vaccine currently available to protect against chlamydia. The UMA vaccine technology would be expected to cover all chlamydial infections, including those caused by chlamydia psittaci, which often results in pneumonia and endocarditis in humans, and chlamydia pneumoniae, which is responsible for some pneumonia, bronchitis, pharyngitis, laryngitis, and sinusitis.